AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$PHVS

Modig Berndt sold $90K of PHVS

Modig Berndt (Chief Executive Officer) sold 2,291 shares of Pharvaris N.V. (PHVS) at $39.40 on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Modig Berndt
Published Sep 15, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The CEO's sale via a pre‑arranged plan is a routine liquidity move; unlikely to drive major price change.

02

Market read

Provides fresh insider data for traders monitoring PHVS; limited broader market effect.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 2/10Novelty 5/10Timing: post‑market 2026‑09‑14

Background

Form 4 filing reveals insider transaction for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

CEO Modig Berndt sold 2,291 shares for $90,276 via a 10b5‑1 plan.

Expected impact

Potential short‑term downward pressure, likely limited to a few cents.

Evidence & confidence

The sale size is modest relative to holdings; market may view it as routine.

Market effects

Sector

Minimal impact on biotech sector; typical insider activity.

Regional

No significant regional effect.

Global

Limited to investors tracking PHVS.

Counterpoint

What could challenge this read

The sale could be a strategic tax‑loss harvest rather than a negative signal.

Key entities

  • Company
    Pharvaris N.V.

    Biotech firm listed on Nasdaq under ticker PHVS.

  • Person
    Modig Berndt

    Chief Executive Officer of Pharvaris.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHVS insider trading history →

Related articles

SEP 12
$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

stocktwits.com2 min
SEP 10
$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

investing.com3 min
SEP 9
$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.

rttnews.com2 min